Fanregratinib Approved for Intrahepatic Cholangiocarcinoma in China: A Novel Oral FGFR1/2/3 Inhibitor
On August 25, 2026, the innovative drug Fanregratinib was approved by NMPA for adult patients…
Articles
Chinese Pharmacy Guide: What to Know About Getting Medicines from China Online
A Chinese pharmacy is an important channel for learning about and accessing medicines available in…
Icotrokinra Approved in China for Plaque Psoriasis: The World’s First Oral IL-23R-Targeted Drug
On August 27, Johnson & Johnson announced that Icotrokinra had been approved by NMPA for…
Targeted and Immunotherapy Drugs for Liver Cancer: Treatment Options and Latest Advances
Liver cancer, especially advanced hepatocellular carcinoma (HCC), is increasingly treated with targeted therapy and immunotherapy…
What Are the Most Common Targeted Cancer Drugs? Key Targets and Treatment Uses
What are the most common targeted cancer drugs? Common targeted cancer drugs include therapies targeting…
Innovative PNH Drug Licancopan Approved in China: Oral CFB Inhibitor for Dual Hemolysis Control
On August 20, NMPA announced the approval of Licancopan Fumarate Capsules, a Class 1 innovative…
Anflekitug Approved in China: A New IL-1β Targeted Treatment Option for Acute Gouty Arthritis
On August 20, 2026, Anflekitug was approved in China as an innovative drug developed by…
China Innovative Oncology Drugs: 15 New Approvals in H1 2026
According to publicly available information, 38 innovative drugs were approved for marketing in China in…
Felzartamab Approved for Multiple Myeloma: Another CD38 Monoclonal Antibody Enters the Chinese Market
Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China…
Tinengotinib Approved for Cholangiocarcinoma in China, Addressing FGFR Inhibitor Resistance
Tinengotinib approved for cholangiocarcinoma marks an important advance for patients with FGFR2 fusion or rearrangement-positive…